Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b study of RH5.2-VLP and R21 malaria vaccines in adults and infants in The Gambia
PACTR202205485639426Phase 1Not yet recruiting
- Sponsor
- University of Oxford
- Start
- Sep 2022
- Modality
- Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of RH5.2-VLP, R21/Matrix-M and Matrix M in malaria (3 arms), sponsored by University of Oxford. Primary endpoints: Solicited local reactogenicity, Solicited systemic reactogenicity and 3 more. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
RH5.2-VLPR21/Matrix-MMatrix M
03
Conditions
malaria
Beyond the preview
Go deeper on PACTR202205485639426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202205485639426.